Skip to search formSkip to main contentSkip to account menu

somatostatin analogue therapy

Known as: Somatostatin Analog Therapy, therapy, somatostatin analogue 
Endocrine drug therapy that uses analogs of somatostatin to treat neuroendocrine tumors.
National Institutes of Health

Related topics

Related topics

1 relation
Hormone Therapy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A case of carcinoid crisis despite high dose somatostatin analogue therapy peri-operatively
2016
2016
Hair loss after transesphenoidal surgery in patient with cured acromegaly
Hair loss has been reported as an adverse effect of somatostatin analog therapy; on the other hand, hair loss after surgical… 
2011
2011
Thyroid Papillary Carcinoma in a Case with Growth Hormone and Thyrotropin Secreting Hormone Co-Secreting Pituitary Macroadenoma
We report a case of growth hormone and thyrotropin secreting hormone (GH/TSH) cosecreting pituitary macro-adenoma who was treated… 
2010
2010
Near-complete regression of liver metastatic lesions in a patient with advanced pancreatic gastrinoma in response to somatostatin analogue therapy following cytoreductive surgery
2009
2009
A hypophysisadenomák kezelése = Treatment of pituitary adenomas
Az agyalapi mirigy terfoglalo folyamatainak prevalenciaja epidemiologiai vizsgalatok alapjan 16,5%, tulnyomo tobbseguk… 
2009
2009
High-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analogue therapy: a randomized, controlled trial
2008
2008
Gamma knife radiosurgery: a safe and effective treatment for acromegaly
We report the use of Gamma knife radiosurgery (GK) to 15 somatotroph adenomas. Eight patients had refractory acromegaly despite… 
Review
2006
Review
2006
Original article Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: A case report and short literature review
Background: Small-cell neuroendocrine carcinoma has been recognized as a rare histologic variant occurring in only 0.5% to 2% of… 
2006
2006
Acute biliary tract problems are common on discontinuation of somatostatin analogue (SA) therapy